The safety and efficacy of repeated dexamethasone intravitreal implants have been demonstrated in patients with BRVO and CRVO-associated macular edema as compared to anti-VEGF injections, with the caveat that functional efficacy decreases and risk for intraocular pressure elevation and cataract progression increases over time with repeated injections [41,42,43,44,45,46,47,48,49]. This evidence concerns the gene VEGFA and macular retinal edema.